Finance / BMY (BRISTOL MYERS SQUIBB CO)

NEW ORLEANS, Nov 10 (Reuters) - Researchers have overestimated the ability to administer Eli Lilly and Co's (LLY.N: Quote, Profile, Research, Stock Buzz) experimental prasugrel blood thinner without causing dangerous bleeding, a prominent cardiologist said on Monday. U.S. regulators in recent months have twice delayed a decision on whether to approve prasugrel, a blood clot preventer being ...

AstraZeneca's Crestor in spotlight at heart meeting Wed Nov 5, 2008 12:49pm EST * AHA meeting begins in New Orleans Saturday * Cholesterol drugs in spotlight By Bill Berkrot NEW YORK, Nov 5 (Reuters) - AstraZeneca's powerful cholesterol fighter Crestor will take center stage at the American Heart Association scientific meeting in New Orleans next week as doctors and ...

  Recs: 8 Wyeth narrows focus of early-stage research - (still will develop Alz. drugs-semi) Wyeth narrows focus of early-stage research Tue Oct 28, 2008 4:43pm EDT   Email  |  Print  |  Share  |  Reprints  |  Single Page  |  Recommend   ( 0 ) [ - ]  Text  [ + ] MARKET NEWS Oil above $65 as ...

also on yahoo news i saw this today- The company, which has been beset by rejections and delays for important experimental drugs and by generic competition for its Protonix ulcer medicine, will focus on sophisticated biotech medicines and ailments treated by specialists. "This is not a cost-reduction effort at all; the dollars spent and number of personnel won't change," said Wyeth ...

DEALTALK-M&A dead? Not for big pharmaceutical companies Wed Oct 22, 2008 11:04am EDT Email | Print | Share| Reprints | Single Page | Recommend (0) [-] Text [+] Market News Dollar races to 2-year peak on global recession fears Wall Street slides as economic fears drag | Video Oil drops 7 percent on U.S. stock build, slowing demand | Video More Business & Investing News... Featured ...

Earnings By Nick Godt U.S. stocks will start the next week with some optimism that the markets recent efforts to stabilize will continue, even as the outlook for the economy and earnings get worse from the fallout of the credit crisis. The Dow industrials managed to close on their first week of gains in five. The broad S&P 500 Index and the Nasdaq ...

Stocks to look for stability along with data, earnings By Nick Godt, MarketWatch Last update: 12:01 a.m. EDT Oct. 18, 2008Comments: 2NEW YORK (MarketWatch) -- U.S. stocks will start the next week with some optimism that the market's recent efforts to stabilize will continue, even as the outlook for the economy and earnings get worse from the fallout of the credit crisis. The Dow ...

Gilead Sciences 3rd-quarter profit rises 27 pct Thu Oct 16, 2008 7:20pm EDT * Gilead posts third-quarter net of 52 cents a share * Gilead product sales rise 39 percent * Gilead sets $750 million accelerated share repurchase * Gilead reaffirms 2008 drug sales outlook By Deena Beasley LOS ANGELES, Oct 16 (Reuters) - Gilead Sciences Inc (GILD.O: Quote, Profile, Research, Stock Buzz) ...

Quote: Originally Posted by Anonymous Bristol says ImClone defeat may have silver lining By Ransdell Pierson NEW YORK, (Reuters) - Bristol-Myers Squibb Co (BMY.N: Quote, Profile, Research, Stock Buzz) on Monday said it exercised financial discipline by abandoning its efforts to buy cancer-drug partner Imclone Systems Inc, but is...